Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Announces Regulatory Acceptance of T-Cell Select™ in China
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced regulatory acceptance of the T-Cell Select kit by the China Food and Drug Administration (CFDA).
View HTML
Toggle Summary Oxford Immunotec to Participate in Two Investor Conferences This Week
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to present at the following investor
View HTML
Toggle Summary Oxford Immunotec Reports Third Quarter 2018 Financial Results
Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT ® .TB tests sold in the third quarter exceeded one million tests for the first time Significant improvement in GAAP net loss; first quarter of positive non-GAAP adjusted EBITDA OXFORD, United Kingdom
View HTML
Toggle Summary Oxford Immunotec Schedules Third Quarter 2018 Earnings Release and Business Update Conference Call for November 9, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2018 financial results prior to market open on Friday, November 9, 2018 .
View HTML
Toggle Summary Quest Diagnostics Completes Acquisition of U.S. Laboratory Services Business of Oxford Immunotec
Oxford Immunotec's T-SPOT®.TB Tuberculosis and Accutix™ Tick-Borne Disease Testing Services are Part of Quest Diagnostics' Portfolio of Innovative Infectious Disease Diagnostics Tests, Broadening Access in the United States SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass., Nov.
View HTML
Toggle Summary Quest Diagnostics to Acquire U.S. Laboratory Services Business of Oxford Immunotec
Acquisition to broaden access to tuberculosis (TB) IGRA blood testing in the United States SECAUCUS, N.J. and OXFORD, England and MARLBOROUGH, Mass. , Sept. 25, 2018 /PRNewswire/ --  Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Oxford Immunotec
View HTML
Toggle Summary Oxford Immunotec Reports Second Quarter 2018 Financial Results
Second quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United States Gross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basis Launch of transformative T-Cell Select™ product to enable full automation of T-SPOT
View HTML
Toggle Summary Oxford Immunotec Launches T-Cell Select™ to Enable Full Automation of the T-SPOT®.TB Test, Provides Unrivaled Sample Stability and Simplicity of Blood Collection
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the new CE-marked T-Cell Select kit in Europe and select ROW countries.
View HTML
Toggle Summary Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 2018
OXFORD, United Kingdom and MARLBOROUGH, Mass. , July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018 . Dr.
View HTML
Toggle Summary Oxford Immunotec Applauds Updated Guidelines from the American Academy of Pediatrics Supporting Expanded Use of the T-SPOT®.TB Test
OXFORD, United Kingdom and MARLBOROUGH, Mass. , June 05, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it applauds updated guidelines from the American Academy of Pediatrics (AAP) on screening for latent
View HTML